Vaccine-induced T-helper 17 (Th17) cells are necessary and sufficient to protect against fungal infection. Although live fungal vaccines are efficient in driving protective Th17 responses and immunity, attenuated fungi may not be safe for human use. Heat-inactivated formulations and subunit vaccines are safer but less potent and require adjuvant to increase their efficacy. Here, we show that interleukin 1 (IL-1) enhances the capacity of weak vaccines to induce protection against lethal Blastomyces dermatitidis infection in mice and is far more effective than lipopolysaccharide. While IL-1 enhanced expansion and differentiation of fungus-specific T cells by direct action on those cells, cooperation with non-T cells expressing IL-1R1 was necessary to maximize protection. Mechanistically, IL-17 receptor signaling was required for the enhanced protection induced by IL-1. Thus, IL-1 enhances the efficacy of safe but inefficient vaccines against systemic fungal infection in part by increasing the expansion of CD4 + T cells, allowing their entry into the lungs, and inducing their differentiation to protective Th17 cells.
Despite the emerging threat of systemic fungal infections worldwide, no commercial antifungal vaccines are now available [1, 2] . This growing medical need has spawned interest in developing such vaccines. Virulence-attenuated mutants induce maximal protection and sterilizing immunity, as demonstrated by the efficacy of experimental vaccines against blastomycosis, histoplasmosis, and coccidiomycosis [3] [4] [5] . Vaccine resistance induced by attenuated mutants is chiefly mediated by CD4
+ T cells [6] [7] [8] ; however, even in the absence of CD4 + T-cell help, protective memory CD8 + T cells can be induced and maintained for a long period [9] .
Experimental vaccines against candidiasis [10] , aspergillosis [11] , and the endemic mycoses owe their protection chiefly to induction of T-helper 17 (Th17) and Thelper 1 (Th1) cells [6] [7] [8] 12 ]. Although we have gained valuable knowledge about rational vaccine design from experimental animal models, live attenuated vaccine strains are not likely to be safe in immunocompromised patients. Whereas subunit or heat-inactivated vaccines are safe, they induce minimal or reduced T-cell responses and protection in the absence of adjuvants.
Infections and vaccination with live fungi induce inflammation and the production of proinflammatory cytokines that promote T-cell expansion and differentiation. We asked here whether interleukin 1β (IL-1β), a proinflammatory cytokine known to increase the expansion and differentiation of antigen-specific CD4 + [13] and CD8 + [14] T cells, can augment antifungal resistance conferred by suboptimal but safe vaccine formulations. IL-1 administered with ovalbumin has been shown to increase the in vivo expansion of antigen-specific Tcell receptor (TCR) transgenic (Tg) CD4 + T cells that produce interleukin 17 (IL-17), interleukin 4 (IL-4), or, to a lesser degree, interferon γ (IFN-γ), by direct action on the responding T cells. In addition, already primed Th1, T-helper 2 (Th2), and Th17 cells expanded better in the presence of IL-1 during secondary stimulation. Memory T cells that were primed in the presence of IL-1 retained their differentiated state during a secondary encounter with antigen, compared with T cells primed by antigen alone. Similarly, CD8 + T cells primed in the presence of IL-1 showed augmented expansion and enhanced expression of granzyme B and IFN-γ and greater cytotoxic activity; these cells retained their expanded numbers and differentiated state when rechallenged 2 months after priming, even if IL-1 was not readministered [14] . Interestingly, trafficking to or retention of primed T cells in the periphery (lung and liver), as well as their increased expression of granzyme B and IFN-γ, required IL-1R1 expression in cells other than antigen-specific T cells. IL-1 administered with heat-killed Listeria monocytogenes resulted in enhanced resistance to subsequent challenge with live L. monocytogenes [14] . To our knowledge, IL-1 has not been tested as an adjuvant for vaccine-induced resistance to fungal infection, a condition for which no commercial vaccines are available and the immunogenicity of existing formulations is generally suboptimal. Moreover, the capacity of IL-1 to preferentially enhance differentiation to Th17 cells suggests it could have particular value in inducing resistance to fungal infection.
Here, we asked several questions: Does IL-1 augment resistance against B. dermatitidis infection conferred by an inefficient heat-inactivated vaccine or its crude cell wall/membrane extract? If so, how does IL-1 mediate its adjuvant effect: directly on T cells, by innate cells, or both? What roles are played by fungusspecific Th17 cells and IL-17 receptor signaling during the adjuvant effect of IL-1? We report that IL-1 adjuvant significantly enhances the resistance mediated by weak vaccines against fungi and does so in a manner that promotes the development of Th17 cells and requires signaling via IL-17R and the contribution of non-T cells that express IL-1R1 for maximal protection.
METHODS

Mouse Strains
Inbred strains of C57BL/6 mice (sex, female; age, 7-8 weeks at the time of experiments) were obtained from Jackson Laboratories (Bar Harbor, ME). Blastomyces-specific TCR Tg 1807 mice were generated in our laboratory and backcrossed to congenic Thy1.1 + mice as described elsewhere [15, 16] . TCR Tg OT-II/ RAG1 −/− C57BL/6 mice and TCR Tg OT-II/RAG1 −/− IL-1R1 −/− C57BL/6 mice were obtained from Taconic farms.
Breeder pairs for IL-17RA −/− mice [17] were provided by Amgen. Mice were housed and cared for according to guidelines of the University of Wisconsin Animal Care Committee, which approved all aspects of this work. 
Fungi and Growth Conditions
Intracellular Cytokine Staining
Lung and draining lymph node cells were obtained as described elsewhere [4] . An aliquot of isolated cells was stained for surface CD4 and Thy 1.1 to determine the percentage of transferred 1807 cells. The number of 1807 cells in the lung and lymph node were derived by multiplying the percentage of cells by the total number of cells per organ isolated. The remaining cells were stimulated with anti-CD3 and anti-CD28 mAbs. After 4-6 hours, cells were stained for surface markers, fixed, permeabilized in Cytofix/Cytoperm kit (BD Pharmingen), and stained with anti-cytokine antibodies as described elsewhere [20, 21] .
Experimental Infection
Mice were infected intratracheally with 2 × 10 3 wild-type yeast of strain ATCC 26199 as described elsewhere [3] . On day 4 after infection, coinciding with the peak of T-cell influx [4, 6] , the mice were euthanized, and lung T cells were analyzed by fluorescence-activated cell sorter analysis.
Statistical Analysis
Differences in the number and percentage of activated, proliferating, or cytokine-producing T cells and in the number of lung colony-forming units (CFU), were analyzed using the Wilcoxon rank test, for nonparametric data [22] , or the t test, when data were normally distributed. A P value of < .05 is considered statistically significant.
RESULTS
Recombinant IL-1 Augments Vaccine Resistance to B. dermatitidis Infection
We tested whether IL-1 enhances vaccine resistance against fungi by using an experimental model of lethal infection with the systemic dimorphic fungus B. dermatitidis. We engineered a live attenuated vaccine that induces sterilizing immunity in response to challenge with virulent, wild-type yeast [3] . To and their entry into the lung, but IL-1R1 + non-T cells are required to promote optimal adjuvant efficacy.
IL-1 Augments the Recruitment of Antifungal Th17 Cells to the Lung Upon Recall
The development of vaccine-induced Th17 cells is necessary and sufficient to protect against systemic dimorphic fungi [12] . To see whether vaccination in the presence of IL-1 increases the frequency and number of IL-17-producing fungus-specific T cells, we enumerated cytokine-producing 1807 cells in the lung upon recall. IL-1 adjuvant increased the frequency and number of IL-17 + 1807 cells and reduced the frequency and number of both IFN-γ and interleukin 13 (IL-13) + antigen-specific 1807 cells recruited to the lung ( Figure 3A and 3B) . IL-1 also increased the frequency of IL-17-producing endogenous CD4 + T cells; however, endogenous IFN-γ and IL-13 producers also increased in frequency when IL-1 was administered ( Figure 3A and data not shown). IL-1 also increased the percentage and numbers of activated (CD44 + ) 1807 cells (data not shown). Thus, IL-1 increased the expansion of fungus-specific 1807 cells and enhanced the Th17 response.
The IL-1 Adjuvant Effect Requires IL-17 Signaling
Since IL-1 increased the number of Th17 cells present in the lung upon challenge (Figure 3) , we investigated whether the production of IL-17 is required for the vaccine-enhancing effect of IL-1. To do so, we vaccinated IL-17RA
−/− mice, in which IL-17 cannot signal via its receptor to mediate its effector functions [12] . We previously reported that Th17 and Th1 cell development and migration to the lung are not impaired in the absence of IL-17R signaling [12] . 
DISCUSSION
Here, we report that IL-1 augmented the protective efficacy of weak antifungal vaccines. We observed that IL-1 given together with a heat-inactivated, whole-yeast vaccine or with a cell-wall membrane extract made from the yeast reduced the number of lung CFU by 1-2 log 10 , compared with values for vaccinated controls that did not receive IL-1. The adjuvant effect of LPS was smaller than that of IL-1, but together the effects were often additive. In previous work, it was shown that the addition of IL-1 to a heat-killed L. monocytogenes vaccine yielded a 2-log 10 reduction in the number of liver CFU upon challenge with live L. monocytogenes, compared with vaccination with heat-killed L. monocytogenes alone [14] . Similarly, IL-1 given with a human immunodeficiency virus (HIV) peptide vaccine increased protection to a recombinant vaccinia virus expressing the HIV peptide by 1 log 10 , compared with the peptide alone, and enhanced the efficacy of a peptide vaccine against a tumor expressing that peptide [14] .
In the experimental bacterial and viral systems noted above, the mechanism through which IL-1 mediated its adjuvant effect was not determined, whereas the antifungal resistance observed here rested chiefly on CD4 + T cells. This conclusion is supported by our use of adoptively transferred 1807 TCR Tg T cells. IL-1R1 +/+ OT2 RAG1 −/− recipients of 1807 cells that were vaccinated in the presence of IL-1 had >4-log 10 fewer lung CFU than did comparable controls that had not received 1807 cells. However, optimal protection mediated by 1807 cells and IL-1 In wild-type recipient mice, priming of 1807 cells in the presence of IL-1 markedly altered their T-helper phenotype. Fungal pathogen-associated molecular patterns such as β-glucan [24] and mannans [25] on non-T cells to induce granzyme B expression, antigen-specific cytotoxic T-cell activity, and production of IFN-γ [14] . Logical target cells for IL-1 in this model are dendritic cells [26, 27] .
In a nasal vaccination model of Bacillus anthracis, IL-1 activated stromal cells to produce IL-6 [27] . Thus, it is possible that IL-1 adjuvant could have enhanced differentiation during the priming of naive 1807 cells into Th17 cells in IL-1R1 +/+ mice but not in IL-1R1 −/− recipients. On the other hand, the capacity of IL-1 to enhance the expansion of antigen-specific CD4 + T cells does not depend on IL-6 since it can be achieved in IL-6-deficient recipients [13] . Highly differentiated T cells that have been primed in the presence of IL-1 retain the capacity to produce elevated levels of cytokine and granzyme B upon rechallenge >4 weeks after priming without readministration of IL-1 [14] . While our study does not pinpoint the timing and mechanism by which IL-1R1-expressing non-T cells contribute to the optimal IL-1 adjuvant effect, it reveals that the protective value of IL-1 (but not its capacity to cause expansion of responding cells) requires action on non-T cells, as well as the responding CD4 + T cells.
Our study establishes that the generation of vaccine-induced Th17 cells is crucial for the IL-1 adjuvant effect for protection against challenge with Blastomyces organisms. Vaccinated IL-17RA −/− mice did not acquire resistance in response to IL-1 treatment, while vaccinated IL-17RA +/+ mice reduced the number of lung CFU by 1-2 log 10 , compared with the value in controls vaccinated without IL-1. This study reinforces the beneficial role that Th17 cells can exert during vaccine immunity despite debate about the possible tissue-damaging influence of inflammation mediated by Th17 cells [28] . In summary, our proof of principle study demonstrates that IL-1 has the capacity to enhance vaccine resistance against fungi, here studied in a model of lethal infection with the systemic fungal pathogen B. dermatitidis. IL-1 promotes the differentiation of fungus-specific Th17 cells that are essential for the adjuvant and vaccine effects while also reducing the generation of antigen-specific Th1 and Th2 cells. Untoward, potent proinflammatory effects will need to be studied to mitigate IL-1 toxicity in the clinical setting. Since fungal glycans have the inherent capacity to induce generation of Th17 cells, perhaps less IL-1 may be sufficient to confer vaccine-induced protection when used together with Th17 cell-promoting fungal ligands or even small amounts of alum as an approved adjuvant, because it also induces IL-1 [13, 29] . In addition, the pyrogenic activity of IL-1 and local inflammation could be reduced in humans by using nonsteroidal antiinflammatory drugs, which do not affect the immunological properties of IL-1 [30] .
Notes
